Skip to main content

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
Read More
Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma
Wayne Kuznar
Read More
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
Read More
Leukemia, Oncology
Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL
Wayne Kuznar
Read More
FDA Approvals
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Lisa A. Raedler, PhD, RPh
Read More
Conference Highlights ASH
Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease
Read More
Conference Highlights ASH
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
Read More
Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
Read More
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
Read More
Perspectives
Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers
Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Page 1 of 4
Results 1 - 10 of 32